Century Therapeutics Maintains $150M ATM Program, With $131.6M Remaining In Capacity

On July 10, 2025, Century Therapeutics, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a shelf registration statement on Form S-3 (File No. 333-288616), which became effective on January 9, 2026, and replaced the Company's previous shelf registration statement on Form S-3 (File No. 333-265975) filed with the SEC on July 1, 2022.

In connection with the effectiveness of the new shelf registration statement, the Company also filed with the SEC a new prospectus supplement (the "Prospectus Supplement"), dated March 26, 2026, with respect to the Company's existing "at the market" equity offering program (the "ATM Program"), pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $150,000,000, from time to time through with Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, as sales agent (the "Sales Agent"), pursuant to a Sales Agreement, dated July 1, 2022, between the Company and the Sales Agent (the "Sales Agreement").

The Company has sold shares of its common stock having an aggregate offering price of $18,380,259 under the ATM Program. Accordingly, as of the date of the Prospectus Supplement, shares of common stock having an aggregate offering price of up to $131,619,741 remain available for offer and sale under the ATM Program.